# A Study to Assess the Safety of SAB-176 to Prevent the Flu, Given IM in Healthy Adults Compared With Placebo

> **NCT06435936** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **SAb Biotherapeutics, Inc.** · enrollment: 28 (actual)

## Conditions studied

- PHA1A

## Interventions

- **DRUG:** Single Ascending Dose of SAB-176
- **DRUG:** Single Ascending Dose of Placebo

## Key facts

- **NCT ID:** NCT06435936
- **Lead sponsor:** SAb Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-22
- **Primary completion:** 2025-02-01
- **Final completion:** 2025-02-01
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06435936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06435936, "A Study to Assess the Safety of SAB-176 to Prevent the Flu, Given IM in Healthy Adults Compared With Placebo". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06435936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*